150 related articles for article (PubMed ID: 15379774)
1. Efalizumab in the treatment of psoriasis.
Leonardi CL
Dermatol Ther; 2004; 17(5):393-400. PubMed ID: 15379774
[TBL] [Abstract][Full Text] [Related]
2. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
4. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
5. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
Cather JC; Cather JC; Menter A
Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
7. [Efalizumab].
Descamps V
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
[TBL] [Abstract][Full Text] [Related]
8. Efalizumab in the treatment of psoriasis.
Gupta AK; Cherman AM
J Cutan Med Surg; 2006; 10(2):57-68. PubMed ID: 17241576
[TBL] [Abstract][Full Text] [Related]
9. Efalizumab: continuous therapy for chronic psoriasis.
Cather JC; Menter A
Expert Opin Biol Ther; 2005 Mar; 5(3):393-403. PubMed ID: 15833076
[TBL] [Abstract][Full Text] [Related]
10. [Efalizumab. Long-term treatment of psoriasis].
Prinz JC
Hautarzt; 2005 Sep; 56(9):812-8. PubMed ID: 16096737
[TBL] [Abstract][Full Text] [Related]
11. Efalizumab.
Wellington K; Perry CM
Am J Clin Dermatol; 2005; 6(2):113-8; discussion 119-20. PubMed ID: 15799683
[TBL] [Abstract][Full Text] [Related]
12. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
[TBL] [Abstract][Full Text] [Related]
13. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
14. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
15. Current concepts and review of efalizumab in the treatment of psoriasis.
Leonardi CL
Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
[TBL] [Abstract][Full Text] [Related]
16. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
[TBL] [Abstract][Full Text] [Related]
17. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
18. Efalizumab: a biological agent for the treatment of psoriasis.
Hodulik S; Hadi S
Rev Recent Clin Trials; 2006 May; 1(2):165-8. PubMed ID: 18473968
[TBL] [Abstract][Full Text] [Related]
19. Efalizumab: an overview.
Leonardi CL
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S98-104. PubMed ID: 12894132
[TBL] [Abstract][Full Text] [Related]
20. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
Schön MP
Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
